SG Americas Securities LLC Reduces Position in Hologic, Inc. (NASDAQ:HOLX)

SG Americas Securities LLC trimmed its stake in Hologic, Inc. (NASDAQ:HOLX) by 91.2% in the 3rd quarter, HoldingsChannel reports. The firm owned 20,109 shares of the medical equipment provider’s stock after selling 209,062 shares during the period. SG Americas Securities LLC’s holdings in Hologic were worth $1,638,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD increased its position in Hologic by 77.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock worth $490,931,000 after buying an additional 2,753,016 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Hologic by 21.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,535,258 shares of the medical equipment provider’s stock valued at $188,243,000 after acquiring an additional 450,190 shares during the period. Black Creek Investment Management Inc. increased its holdings in Hologic by 60.9% in the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock worth $173,669,000 after acquiring an additional 885,524 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Hologic by 5.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,326,992 shares of the medical equipment provider’s stock worth $172,780,000 after acquiring an additional 124,739 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in Hologic by 4.0% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,271,603 shares of the medical equipment provider’s stock valued at $168,666,000 after purchasing an additional 87,176 shares in the last quarter. 94.73% of the stock is owned by institutional investors.

Hologic Trading Up 0.5 %

HOLX stock opened at $80.26 on Wednesday. The firm has a fifty day moving average price of $81.24 and a 200 day moving average price of $77.51. Hologic, Inc. has a fifty-two week low of $64.02 and a fifty-two week high of $84.67. The firm has a market cap of $18.73 billion, a PE ratio of 40.95, a price-to-earnings-growth ratio of 2.58 and a beta of 0.98. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.32 and a current ratio of 3.99.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The business’s revenue was up 2.7% on a year-over-year basis. During the same period last year, the company posted $0.93 EPS. Sell-side analysts anticipate that Hologic, Inc. will post 4.09 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Christiana Stamoulis sold 9,039 shares of the stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total transaction of $718,600.50. Following the sale, the director now owns 45,472 shares in the company, valued at approximately $3,615,024. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, Director Christiana Stamoulis sold 9,039 shares of the company’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total transaction of $718,600.50. Following the transaction, the director now directly owns 45,472 shares in the company, valued at approximately $3,615,024. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Benjamin Jordan Cohn sold 5,093 shares of the firm’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $81.99, for a total transaction of $417,575.07. Following the completion of the sale, the insider now directly owns 10,476 shares of the company’s stock, valued at approximately $858,927.24. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 18,280 shares of company stock valued at $1,469,973 in the last ninety days. Insiders own 1.75% of the company’s stock.

Wall Street Analysts Forecast Growth

HOLX has been the subject of a number of analyst reports. Mizuho increased their price objective on shares of Hologic from $85.00 to $90.00 and gave the stock an “outperform” rating in a research note on Friday, October 4th. JPMorgan Chase & Co. raised their price target on Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a report on Tuesday, July 30th. Royal Bank of Canada restated a “sector perform” rating and issued a $82.00 price objective on shares of Hologic in a research report on Friday, August 16th. Evercore ISI increased their target price on Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. Finally, Stephens reissued an “overweight” rating and issued a $92.00 price target on shares of Hologic in a report on Tuesday, July 30th. Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $87.50.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.